COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Bronstein, Yotam; Gat, Roi; Levi, Shai; Cohen, Yaël; Luttwak, Efrat; Benyamini, Noam; Shragai, Tamir; Vitkon, Roy; Neaman, Miriam; Eilaty, Nili; Levi, Mor; Trestman, Svetlana; Perry, Chava; Herishanu, Yair; Avivi, Irit

doi:10.1016/j.ccell.2022.04.015

Cited by 12 publications

(25 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of doubt, a panel discussion was performed. ALL: Acute lymphocytic leukaemia; AML: Acute myeloid leukaemia; CLL: Chronic lymphocytic leukaemia; MM: multiple myeloma; NHL: Non-Hodgkin lymphoma; HL: Hodgkin lymphoma; HFNC: High-flow nasal cannula; CPAP: continuous positive airway pressure In line with the literature [18,[34][35][36][37], we found a reduction on ICU admission rates. These findings may be explained with the lower need of high-level oxygen support (i.e.…”

Section: Discussionsupporting

confidence: 87%

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

et al. 2023

View full text Add to dashboard Cite

Patients with haematological malignancies (HM) and SARS-CoV-2 infection present a higher risk of severe COVID-19 and mortality. The aim of the study was to investigate whether vaccination and monoclonal antibodies (mAbs) have modified the outcomes of HM patients with COVID-19. This is a single-centre retrospective study in HM patients hospitalized due to SARS-CoV-2 infection from March 2020 to April 2022. Patients were divided into PRE-V-mAb group (patients hospitalized before the introduction of vaccination and mAbs) and POST-V-mAb group (patients hospitalized after the use of vaccine and mAbs). A total of 126 patients were included (65 PRE-V-mAb and 61 POST-V-mAb). POST-V-mAb patients showed a significantly lower risk of intensive care unit (ICU) admission (8.2% vs. 27.7%, p = 0.005), shorter viral shedding [17 (IQR 10–28) vs. 24 days (IQR 15–50), p = 0.011] and shorter hospitalization length [13 (IQR 7–23) vs. 20 (IQR 14–41) days, p = 0.0003] compared to the PRE-V-mAb group. Nevertheless, both in-hospital and 30-day mortality rates did not significantly differ between the two groups (29.5% POST-V-mAb vs. 36.9% PRE-V-mAb and 21.3% POST-V-mAb vs. 29.2% PRE-V-mAb, respectively). At the multivariable analysis, an active malignancy (p = 0.042), a critical COVID-19 at admission (p = 0.025) and the need for high-level of oxygen support at respiratory worsening [either HFNC/CPAP (p = 0.022) or mechanical ventilation (p = 0.011)] were independently associated with in-hospital mortality. In the subgroup of POST-V-mAb patients, receiving therapy with mAbs was a protective factor (p = 0.033). Despite the new therapeutic and preventive strategies available, HM patients with COVID-19 disease represent an extremely vulnerable group with still high mortality rates.

show abstract

Section: Discussionsupporting

confidence: 87%

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Moreover, the lower proportion of cases with severe disease in the general population may be in uenced by the high number of infected individuals (17). The clinical outcome after COVID-19 among patients with CLL seems to have improved in the Omicron era (3) even though the fatality rate was still as high as 23% among patients with close hospital contacts in a Danish registry-based report (18) and 31% in hospitalized patients in Israel (19).…”

Section: Introductionmentioning

confidence: 99%

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia

Ingelman-Sundberg

Blixt

Wullimann

et al. 2023

Preprint

View full text Add to dashboard Cite

Patients with chronic lymphocytic leukemia (CLL) were at high risk early in the COVID-19 pandemic. The Omicron SARS-CoV-2 variant is considered less aggressive, but a significant fatality rate was recently reported from CLL register studies. Here we report on Omicron hybrid immunity in CLL after vaccinations against SARS-CoV-2 followed by disease. Post-infection systemic and mucosal immunity against SARS-CoV-2 were analyzed in patients with CLL (n = 38) during the Omicron BA.1/BA.2 time-period. Most patients (30/38, 79%) had received 3 to 4 vaccine doses, yet median anti-Spike antibody titers were 0 U/mL (range 0–6,528) at the onset of infection. Significantly elevated serum antibody levels were observed post-infection (p = 0.0027 vs baseline) to a median of 3,145 U/mL (range 0->25 000) which correlated with inhibition of Spike-ACE2 binding. Low convalescent IgA responses were noted in both saliva and serum in patients with ongoing BTKi/BCL-2i therapy compared with early-stage untreated patients (p = 0.010; p = 0.051). Post-Omicron CD4 + and CD8 + T cell responses were observed at levels similar to those of healthy donors. Forty-seven percent of the patients required hospitalization but there was only one possibly related death. Broad immunity was observed in patients with CLL following Omicron infection. Impaired mucosal immunity during BTKi therapy requires further studies.

show abstract

“…

Recent studies performed during the early period (December 2021-April 2022) of the omicron (B.1.1.529) variant of concern and its subvariants, suggested favourable clinical outcomes compared with earlier SARS-CoV-2 variants in patients with chronic lymphocytic leukaemia (CLL). [1][2][3] However, the outcomes of CLL patients infected in the later period of the omicron subvariants are not fully elucidated.In this single-center, retrospective study, we analysed the all-cause hospitalization and 30-day mortality of CLL patients infected with SARS-CoV-2 from December 2021 through November 2022. The diagnosis of SARS-CoV-2 infection was confirmed by a positive reverse transcriptionpolymerase chain reaction assay or an antigen test at authorized testing sites on nasopharyngeal swabs.

…”

mentioning

confidence: 99%

“…Recent studies performed during the early period (December 2021-April 2022) of the omicron (B.1.1.529) variant of concern and its subvariants, suggested favourable clinical outcomes compared with earlier SARS-CoV-2 variants in patients with chronic lymphocytic leukaemia (CLL). [1][2][3] However, the outcomes of CLL patients infected in the later period of the omicron subvariants are not fully elucidated.…”

mentioning

confidence: 99%

“…From the beginning of the Omicron surge in mid-December 2021, there has been a continuous improvement in the clinical outcomes, manifested in a decrease in COVID-19-related hospitalization and mortality rates. While, several studies have reported the outcomes of patients with CLL when the BA.1 and the BA.2 subvariants became the most dominant strains, 1,3 this study also refers to the period dominated by the BA.5.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge

2023

Self Cite

View full text Add to dashboard Cite

Summary Patients with chronic lymphocytic leukaemia (CLL) infected with SARS‐CoV‐2 are at increased risk of severe COVID‐19 and death. The outcomes of CLL patients with COVID‐19 during the omicron subvariants and in particular with BA.5 are not fully elucidated. Here, we report the outcomes of 128 CLL patients diagnosed with COVID‐19 from December 2021 through November 2022. The hospitalization and 30‐day mortality rates were 26.6% (n = 34) and 4.7% (n = 6), respectively. Both hospitalizations and mortality were lower during the outbreaks of the BA.2 and BA.5 subvariants (17.2%, 0% vs. 15.2%, 0%, respectively) compared with the period dominated by the BA.1 subvariant (41.5%, 11.3%).

show abstract

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Cited by 12 publications

References 10 publications

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia

Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge

Contact Info

Product

Resources

About